Effects of the Btk-Inhibitors Remibrutinib (LOU064) and Rilzabrutinib (PRN1008) With Varying Btk Selectivity Over Tec on Platelet Aggregation and in vitro Bleeding Time

Background: Bruton tyrosine kinase inhibitors (BTKi) are used in B-cell malignancies and in development against various autoimmune diseases. Since Btk is also involved in specific pathways of platelet activation, BTKi might be considered to target platelet GPVI/GPIb-mediated atherothrombosis and pla...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Rundan, Goldmann, Luise, Brandl, Richard, Spannagl, Michael, Weber, Christian, Siess, Wolfgang, von Hundelshausen, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498029/
https://www.ncbi.nlm.nih.gov/pubmed/34631841
http://dx.doi.org/10.3389/fcvm.2021.749022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498029/
https://www.ncbi.nlm.nih.gov/pubmed/34631841
http://dx.doi.org/10.3389/fcvm.2021.749022

Ejemplares similares